Abeona Therapeutics ABEO 深 沪
已收盘 10-02 16:00:00 美东时间
5.03
+0.020
+0.40%
华盛通- 最 高5.105
- 今 开5.09
- 成交量 121.35万股
- 最 低 4.985
- 昨 收 5.01
- 总市值 2.88亿
- 52周最高 7.65
- 市盈率 静 4.96
- 换手率 2.12%
- 52周最低 4.00
- 委 比 80.98%
- 总股本 5718.40万
- 历史最高 750.00
- 量 比 1.11
- 振 幅 2.40%
- 历史最低 2.19
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics Inc. granted restricted stock equity awards to two new non-executive employees, totaling up to 7,200 shares. The shares vest annually over three years, contingent on continued employment. Abeona is a biopharmaceutical company developing cell and gene therapies, including ZEVASKYN® for recessive dystrophic epidermolysis bullosa and ABO-701 for solid tumors.
10-02 11:30
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank cut the price target for Xenon Pharmaceuticals Inc (NASDAQ:XENE) from $90 to $46. Deutsche Bank ...
09-18 20:31
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
09-17 18:09
Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®
Abeona Therapeutics has activated the University of Florida Health (UF Health) as the eighth Qualified Treatment Center (QTC) for administering ZEVASKYN, the first and only autologous gene-modified cellular sheets for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). This expansion aims to increase access to the innovative gene therapy for patients in Florida and the southeastern United States. ZEVASKYN addresses...
09-16 11:30
Abeona Therapeutics Updates Investor Presentation at Conference
Abeona Therapeutics ( ($ABEO) ) has shared an update. Abeona Therapeutics Inc. ...
09-16 00:47
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
08-15 01:00
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
Abeona Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-13 19:59
